Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial spondyloarthritis (r-axSpA) and elevated or normal/low baseline inflammation, measured by serum C-reactive protein (CRP) or spinal MRI, using data from 2 randomized, double-blind, placebo-controlled phase III t...
Gespeichert in:
Veröffentlicht in: | Rheumatology (Oxford, England) England), 2022-11, Vol.61 (11), p.4324-4334 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial spondyloarthritis (r-axSpA) and elevated or normal/low baseline inflammation, measured by serum C-reactive protein (CRP) or spinal MRI, using data from 2 randomized, double-blind, placebo-controlled phase III trials.
Biologic-naive (COAST-V) or tumor necrosis factor inhibitor-experienced (COAST-W) adults with active r-axSpA received 80 mg ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W) or placebo (PBO); or active reference (40 mg adalimumab Q2W; ADA) in COAST-V. At week 16, patients receiving ixekizumab continued as assigned; patients receiving PBO or ADA were re-randomized 1:1 to IXEQ2W or IXEQ4W through week 52. ASAS40 response rates were examined by baseline CRP (≤5 or > 5 mg/l) and SPARCC MRI spine inflammation score ( |
---|---|
ISSN: | 1462-0324 1462-0332 |
DOI: | 10.1093/rheumatology/keac104 |